Analysts See $0.19 EPS for LeMaitre Vascular, Inc. (LMAT)

January 18, 2018 - By Darrin Black

 Analysts See $0.19 EPS for LeMaitre Vascular, Inc. (LMAT)
Investors sentiment is 1.71 in 2017 Q3. Its the same as in 2017Q2. It is flat, as 11 investors sold LeMaitre Vascular, Inc. shares while 38 reduced holdings. only 27 funds opened positions while 57 raised stakes. 13.06 million shares or 7.12% more from 12.19 million shares in 2017Q2 were reported.
Perkins has invested 3.02% in LeMaitre Vascular, Inc. (NASDAQ:LMAT). 28,000 are owned by Needham Mngmt Limited Liability. New York-based Goldman Sachs Group Incorporated has invested 0% in LeMaitre Vascular, Inc. (NASDAQ:LMAT). Metropolitan Life Insurance Ny holds 11,330 shares or 0% of its portfolio. Thrivent Financial For Lutherans invested in 0% or 9,180 shares. First Mercantile invested in 0.03% or 4,849 shares. Colonial Advsrs has 14,407 shares. Aqr Capital Management Llc holds 0.01% or 213,624 shares in its portfolio. Texas Permanent School Fund holds 10,971 shares. Raymond James Associate holds 0% of its portfolio in LeMaitre Vascular, Inc. (NASDAQ:LMAT) for 5,362 shares. State Street Corp has invested 0% of its portfolio in LeMaitre Vascular, Inc. (NASDAQ:LMAT). Renaissance Tech Ltd Liability Corporation holds 252,600 shares. Pnc Financial Service Grp accumulated 81 shares or 0% of the stock. Wells Fargo And Mn accumulated 134,482 shares. Envestnet Asset has 0% invested in LeMaitre Vascular, Inc. (NASDAQ:LMAT).

Since August 1, 2017, it had 0 insider buys, and 11 sales for $11.10 million activity. 48,317 shares valued at $1.60 million were sold by Roberts David B on Friday, August 4. $1.01M worth of LeMaitre Vascular, Inc. (NASDAQ:LMAT) was sold by LeMaitre George W. Jasinski Lawrence J also sold $69,487 worth of LeMaitre Vascular, Inc. (NASDAQ:LMAT) on Thursday, August 17.

Analysts expect LeMaitre Vascular, Inc. (NASDAQ:LMAT) to report $0.19 EPS on February, 20.They anticipate $0.06 EPS change or 46.15 % from last quarter’s $0.13 EPS. LMAT’s profit would be $3.66 million giving it 43.24 P/E if the $0.19 EPS is correct. After having $0.25 EPS previously, LeMaitre Vascular, Inc.’s analysts see -24.00 % EPS growth. The stock increased 0.37% or $0.12 during the last trading session, reaching $32.86. About 136,203 shares traded. LeMaitre Vascular, Inc. (NASDAQ:LMAT) has risen 101.07% since January 18, 2017 and is uptrending. It has outperformed by 84.37% the S&P500.

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Ratings Coverage

Among 11 analysts covering LeMaitre Vascular (NASDAQ:LMAT), 6 have Buy rating, 0 Sell and 5 Hold. Therefore 55% are positive. LeMaitre Vascular had 35 analyst reports since July 29, 2015 according to SRatingsIntel. TH Capital maintained the stock with “Buy” rating in Monday, December 7 report. The stock of LeMaitre Vascular, Inc. (NASDAQ:LMAT) has “Buy” rating given on Monday, December 7 by Dougherty & Company. The stock of LeMaitre Vascular, Inc. (NASDAQ:LMAT) earned “Hold” rating by Canaccord Genuity on Friday, October 27. The rating was maintained by Canaccord Genuity on Tuesday, May 3 with “Buy”. The stock of LeMaitre Vascular, Inc. (NASDAQ:LMAT) earned “Buy” rating by Benchmark on Wednesday, July 29. Stifel Nicolaus maintained it with “Buy” rating and $35.0 target in Friday, October 27 report. The company was downgraded on Thursday, September 22 by Sidoti. On Thursday, September 10 the stock rating was initiated by Barrington Research with “Mkt Perform”. The stock of LeMaitre Vascular, Inc. (NASDAQ:LMAT) earned “Neutral” rating by Sidoti on Wednesday, January 20. On Tuesday, May 3 the stock rating was maintained by Roth Capital with “Buy”.

LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company has market cap of $633.05 million. The firm provides angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; carotid shunts to temporarily divert or shut blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; and powered phlebectomy devices that enable removal of varicose veins. It has a 42.07 P/E ratio. It also offers embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude blood flow; and perfusion catheters that temporarily perfuse blood and other liquids into the vasculature.

More notable recent LeMaitre Vascular, Inc. (NASDAQ:LMAT) news were published by: Seekingalpha.com which released: “LeMaitre Vascular’s (LMAT) CEO George LeMaitre on Q3 2017 Results – Earnings …” on October 26, 2017, also Nasdaq.com with their article: “LeMaitre Vascular, Inc. (LMAT) Ex-Dividend Date Scheduled for August 21, 2017” published on August 18, 2017, Nasdaq.com published: “Why LeMaitre Vascular (LMAT) Could Be Positioned for a Surge” on August 21, 2017. More interesting news about LeMaitre Vascular, Inc. (NASDAQ:LMAT) were released by: Seekingalpha.com and their article: “LeMaitre Vascular’s (LMAT) CEO George LeMaitre on Q2 2017 Results – Earnings …” published on July 28, 2017 as well as Globenewswire.com‘s news article titled: “LeMaitre Vascular Will Announce Second Quarter 2017 Earnings Results on July …” with publication date: July 13, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.